General MedicationsINJECTIONStandard
AMIKACIN SULFATE
AMIKACIN SULFATE
Standard Dose
EQ 250MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview AMIKACIN SULFATE is listed in Drugs@FDA under application 218146 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient AMIKACIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/ML Sponsor QILU Submission history Latest submission status date: 2024-03-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview AMIKACIN SULFATE is listed in Drugs@FDA under application 218146 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AMIKACIN SULFATE Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/ML Sponsor QILU Submission history Latest submission status date: 2024-03-19 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.